Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forSouth Carolina

Map
South Carolina
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$3.7 million
to South Carolina research institutions
South Carolina

Neglected diseases in South Carolina

Chikungunya cases
Chikungunya cases
25
Dengue cases
Dengue cases
40
HIV diagnoses
HIV diagnoses
6577
Malaria cases
Malaria cases
56
Tuberculosis cases
Tuberculosis cases
1164
West Nile cases
West Nile cases
52
Zika cases
Zika cases
61
South Carolina's top USG-funded global health R&D institutions

South Carolina's top USG-funded global health R&D institutions

University of South Carolina at Columbia
$1.6 million
Clemson University
$1.4 million
Medical University of South Carolina
$723 thousand
South Carolina industry in global health R&D

South Carolina industry in global health R&D

BioAbChem
Location(s): Ladson
Charles River Laboratories
Location(s): Charleston
Coastal Carolina Research Center
Location(s): Mount Pleasant

South Carolina's top areas of global health R&D by USG funding

33.3%
Tuberculosis
29.6%
Salmonella infections
33.1%
Neglected tropical diseases
Kinetoplastids
Global health R&D at work in South Carolina
Global health R&D at work in South Carolina

Clemson University researchers are seeking new treatments for sleeping sickness, a dis-ease that threatens millions of people in sub-Saharan Africa. Infection begins with the bite of a tsetse fly carrying a deadly parasite. Because the parasite also infects and kills livestock, it is a major obstacle to economic development in the region. Existing treatments are difficult to administer and can be toxic, even fatal. The scientists are studying metabolic targets that could lead to a cure. They aim to cut off the parasites from their source of energy: sugar. Molecules that show promise will be evaluated as potential drugs. If successful, the work could lead to treatments for other parasitic infections, such as Chagas disease and leishmaniasis.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Case study photo: PATH/Georgina Goodwin
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

Site managed by A3CS

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In